Promoting Tolerance to Peanut in High-Risk Children (LEAP)
Eczema, Egg Allergy, Food Allergy
About this trial
This is an interventional treatment trial for Eczema focused on measuring peanut allergy, egg allergy, eczema, peanut, allergy, allergies, allergic reaction, anaphylaxis, infants, children
Eligibility Criteria
Inclusion Criteria: Able to consume solid food Allergy to eggs and/or severe eczema Informed consent obtained from parent or guardian. Exclusion Criteria: Clinically significant chronic illness. Participants with eczema or recurrent wheeze are not excluded. Positive skin prick test for peanut allergen with a wheel diameter greater than 4 mm in the presence of a negative saline control Previous or current consumption of peanut protein that exceeds 0.2 g of peanut protein on at least one occasion or 0.5 g over a single week Investigator-suspected allergy to peanut protein Investigator-suspected allergy to peanut protein in care provider or current household member. Diagnosis of persistent asthma ALT (SGPT) or bilirubin greater than 2 times the upper limit of age-related normal value BUN or creatinine greater than 1.25 times the upper limit of age-related normal value Platelet count less than 100,000/mL, hemoglobin less than 9 g/dL, or investigator-suspected immunocompromise Unwillingness or inability to comply with study requirements and procedures
Sites / Locations
- Evelina Children's Hospital, Guy's & St Thomas' NHS Foundation Trust
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Peanut Consumption Group
Peanut Avoidance Group
Participants on this arm will consume peanut protein.
Participants on this arm will avoid peanut as per United Kingdom (UK) public health recommendations.